Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab +/- Capecitabine in Elderly mCRC
NCT01718808Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Nov 2012
- Primary completion
- Dec 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by Swiss Group for Clinical Cancer Research. Started Nov 2012; status: terminated.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01718808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01718808.